Bioauxilium Introduces THUNDER™, a New Generation of TR‑FRET Cell Signaling Assay Kits
19 Febrero 2020 - 8:44AM
Business Wire
THUNDER™ assay kits are the first real,
cost-effective alternatives to ELISAs and other proprietary TR‑FRET
or bead-based assay technologies that will allow researchers
worldwide to generate trustworthy data faster
Bioauxilium Research Inc., a Canadian biotech specialized in the
development and manufacturing of world-class time-resolved F�rster
resonance energy transfer (TR‑FRET) assay kits, announced today the
launch of its proprietary no-wash THUNDER™ TR‑FRET cellular
platform with the introduction of 68 new cell signaling assay kits.
These top-quality, fully validated yet affordable cell-based kinase
kits were designed to enable the simple, rapid and sensitive
semi-quantitative detection of specific intracellular
phosphorylated and/or total proteins in cell lysates.
The ready-to-use THUNDER™ Cell Signaling Assay Kits are
based on the higher specificity sandwich immunoassay format.
However, in contrast to both conventional and improved ELISAs, they
use a no-wash protocol with only one reagent addition and
incubation step. This streamlined protocol dramatically decreases
hands-on time and assay variability and is easily amenable to
automation for high-throughput screening (HTS). The assays can be
run in the same low volume using either half-area 96-well or
low-volume 384-well plates.
The THUNDER™ assay kits combine rigorously validated
antibodies, the best compatible FRET fluorophores and stringent
manufacturing standards to ensure specificity, enhanced TR‑FRET
assay performance and lot-to-lot consistency. All kits are
subjected to a rigorous validation process using lysates from cells
treated with pathway-specific activators and inhibitors, to further
confirm target specificity and demonstrate performance under real
assay conditions. Validation data are included in the accompanying
datasheets, the most comprehensive on the market. All kits are
available in several kit sizes suitable for both lab-scale
experiments and high-throughput screens.
“THUNDER™ is an affordable cell-based assay platform that
provides easy access to the powerful TR‑FRET technology for all
researchers looking to quantify low amounts of endogenous proteins
in cells,” said Jaime Padros, Ph.D., President, Bioauxilium. “We
believe THUNDER™ provides for the first time a real, cost-effective
alternative to ELISAs and other proprietary TR‑FRET as well as
bead-based assay technologies.”
THUNDER™ kits are available worldwide and can be purchased
directly through the Bioauxilium website or through one of
Bioauxilium’s authorized distributors.
The THUNDER™ TR‑FRET technology is also available on request to
Bioauxilium’s customers for custom antibody labelling and assay
development services.
For more information on Bioauxilium and THUNDER™, visit
www.bioauxilium.com.
About Bioauxilium Research Inc. Bioauxilium is a private
Canadian biotechnology company founded by expert industry
scientists. It focuses on the design, development and manufacturing
of top-quality, fully-validated assay kits that simplify laboratory
workflow and accelerate biomedical research. Since its inception in
2013, Bioauxilium has licensed hundreds of TR‑FRET assay kits
enabling the quantification of cellular proteins and biomarkers.
Bioauxilium’s kits are based on its proprietary THUNDER™ TR-FRET
technology. They are offered at an outstanding value and are
supported by expert technical support. Bioauxilium also provides on
a contract basis customized services in assay development using
diverse technologies.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005603/en/
Jaime Padros, President 514-312-9033 ext. 101
jaime.padros@bioauxilium.com